SignalSilence ® c-Myc siRNA I from Cell Signaling Technology

Product Specs
ItemSignalSilence ® c-Myc siRNA I
CompanyCell Signaling Technology
Price $369.00 Inquire
Catalog Number6341S
Quantity300 µl
ApplicationssiRNA
TargetMyc
Molecular Weight64-67 kDa
ReactivityH
TypesiRNA
NCBI Gene AliasesMRTL, MYCC, bHLHe39, c-Myc
NCBI Full Gene NameMYC proto-oncogene, bHLH transcription factor
Research AreaApoptosis

Add to Compare List

Cell Signaling Technology

3 Trask Lane

Danvers, Massachusetts 01923

United States

Phone: 877-616-CELL
Phone: 978-867-2388
Fax: 866-432-6112
Fax: 978-867-2488

Company Profile

Website: http://www.cellsignal.com/

Website: Technical Support

(1) CF10/LV overcomes acquired resistance to 5-FU/LV in colorectal cancer cells through downregulation of the c-Myc/ABCB5 axisCancer Drug ResistanceJuly 15, 2025Charles Chidi Okechukwu, William H. Gmeinercontrol siRNA (Cell Signaling Technology Cat# 6568) and c-Myc siRNA (Cell Signaling Technology Cat# 6341) for 48 h as recommended by the vendor. The cells were lysed using RIPA buffer (50 mM Tris HCl at pH

(2) Discovery Proteomics Analysis Determines That Driver Oncogenes Suppress Antiviral Defense Pathways Through Reduction in Interferon-β Autocrine StimulationMolecular & Cellular ProteomicsJuly 1, 2022Paige E. Solomon, Lisa L. Kirkemo, Gary M. Wilson, Kevin K. Leung, Mark H. Almond, Leanne C. Sayles, E. Alejandro Sweet-Cordero, Oren S. Rosenberg, Joshua J. Coon, James A. WellsAM4611/Thermo Scientific, Cat# 4390843) or target siRNA (MYC/GAPDH) (Cell Signaling Technology, Cat# 6341S/Thermo Scientific, Cat# 4390849) were transfected with lipofectamine (Thermo Scientific, L3000–008)

(3) Biological significance of MYC and CEBPD coamplification in urothelial carcinoma: Multilayered genomic, transcriptional and posttranscriptional positive feedback loops enhance oncogenic glycolysisClinical and translational medicineDecember 1, 2021Chan TC, Chen YT, Tan KT, Wu CL, Wu WJ, Li WM, Wang JM, Shiue YL, Li CF.detect mitochondrial fission and fusion events. SignalSilence c‐Myc small interfering RNAs (siRNAs) (6341, 6552; Cell Signaling Technology, USA) were used for the knockdown of MYC expression. Analysis of promoter

(4) Aurora kinase A inhibition reverses the Warburg effect and elicits unique metabolic vulnerabilities in glioblastomaNature communicationsSeptember 1, 2021Nguyen TTT, Shang E, Shu C, Kim S, Mela A, Humala N, Mahajan A, Yang HW, Akman HO, Quinzii CM, et al.(L-005111-00-0005), and CPT1A siRNA (L-009749-00-0005) were purchased from Dharmacon. Myc-1 siRNA (CST 6341) and Myc-2 siRNA (CST 6552) were purchased from Cell Signaling. For ectopically expressed experiments,

(5) HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma modelsThe Journal of clinical investigationJuly 1, 2020Nguyen TTT, Zhang Y, Shang E, Shu C, Torrini C, Zhao J, Bianchetti E, Mela A, Humala N, Mahajan A, et al.(L-003495-020005), CPT1A siRNA (L-009749-00-0005), and CPT1A-4 siRNA (J-009749-09-0005). Myc-1 siRNA (CST, 6341) and Myc-2 siRNA jci.org Volume 130 Number 7 July 2020 3713 RESEARCH ARTICLE (CST, 6552)

(6) Novel ubiquitin-independent nucleolar c-Myc degradation pathway mediated by antizyme 2Scientific ReportsDecember 1, 2018Noriyuki Murai, Yasuko Murakami, Ayasa Tajima, Senya MatsufujiSASI_Hs01_00196643 (Sigma); Human Fbxw7, siGENOME SMART pool M-004264–02–0005 (Dharmacon); and c-Myc, SignalSilence #6341 (Cell Signaling Technology); and Human NPM1, MISSION EHU115611-20UG (Sigma). All siRNAs are designed

(7) Knockdown of metadherin inhibits cell proliferation and migration in colorectal cancerOncology reportsOctober 1, 2018Li JW, Huang CZ, Li JH, Yuan JH, Chen QH, Zhang WF, Xu ZS, Liu YP, Li Y, Zhan MX, et al.for 1 h at room temperature, prior to being incubated with primary antibodies against C‑Myc (cat no., 6341S; dilution, 1:1,000; Cell Signaling Technology, Inc., Danvers, MA, USA), GAPDH (cat. no., SC‑32233, dilution,

(8) Coupling of the polyamine and iron metabolism pathways in the regulation of proliferation: Mechanistic links to alterations in key polyamine biosynthetic and catabolic enzymesBiochimica et biophysica acta. Molecular basis of diseaseSeptember 1, 2018Lane DJR, Bae DH, Siafakas AR, Suryo Rahmanto Y, Al-Akra L, Jansson PJ, Casero RA Jr, Richardson DR.extracted and western blot analysis performed. In some experiments, SignalSilence® c-Myc siRNA I (Cat. #: 6341; Cell Signaling Technology; Danvers, MA) and TP53 MISSION® endonuclease-digested siRNA pools (esiRNA;

(9) Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibitionOncogeneMay 11, 2017Mateo F, Arenas EJ, Aguilar H, Serra-Musach J, de Garibay GR, Boni J, Maicas M, Du S, Iorio F, Herranz-Ors C, et al.

(10) Novel Thiosemicarbazones Inhibit Lysine-Rich Carcinoembryonic Antigen–Related Cell Adhesion Molecule 1 (CEACAM1) Coisolated (LYRIC) and the LYRIC-Induced Epithelial-Mesenchymal Transition via Upregulation of N-Myc Downstream-Regulated Gene 1 (NDRG1)Molecular PharmacologyMay 1, 2017Ruxing Xi, Ivan Ho Yuen Pun, Sharleen V. Menezes, Leyla Fouani, Danuta S. Kalinowski, Michael L.H. Huang, Xiaozhi Zhang, Des R. Richardson, Zaklina Kovacevic37°C. c-Myc was silenced in the sh-NDRG1 and sh-Ctrl cells using SignalSilence siRNA (si-c-Myc; cat. 6341S; 100 pM; Cell Signaling Technology, Danvers, MA) or the Negative Control siRNA (100 pM) using LipofectAMINE

(11) Prostaglandin E2 promotes the cell growth and invasive ability of hepatocellular carcinoma cells by upregulating c-Myc expression via EP4 receptor and the PKA signaling pathwayOncology reportsOctober 1, 2014Xia S, Ma J, Bai X, Zhang H, Cheng S, Zhang M, Zhang L, Du M, Wang Y, Li H, et al.**P<0.01 compared with the control. PGE2, prostaglandin E2. The siRNA reagents specific to c-Myc (no. 6341) and CREB (no. 6588) were from Cell Signaling Technology. Huh-7 cells (2x105) were plated in 6-well

(12) Histone demethylase KDM5B collaborates with TFAP2C and Myc to repress the cell cycle inhibitor p21(cip) (CDKN1A)Molecular and cellular biologyMay 1, 2012Wong PP, Miranda F, Chan KV, Berlato C, Hurst HC, Scibetta AG.siRNA (no. 1022076; Qiagen) or with validated siRNA targeting KDM5B (J-009899-06; Darmacon) or Myc (6341; Cell Signaling). The following antibodies for Western blotting (Santa Cruz unless stated otherwise)

(13) PICK1 regulates AMPA receptor endocytosis via direct interactions with AP2 α-appendage and dynaminThe Journal of cell biologyJanuary 1, 0001Fiuza M, Rostosky CM, Parkinson GT, Bygrave AM, Halemani N, Baptista M, Milosevic I, Hanley JG.

Be the First to Write a Review!